On Jan. 15. 1999, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommended DTaP vaccines for all five doses in the vaccination schedule, because local reactions, fever, and other systemic events were found to occur substantially less often after DTaP administration than after administration of whole cell DTP.